Engineering activated protein C to maximize therapeutic efficacy.

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Therapeutics
• Immunology and Inflammation

Background:

• Activated protein C (APC) is a key regulator of thrombosis and inflammation.
• Recombinant APC (Xigris) was used for severe sepsis but withdrawn due to bleeding risk and limited efficacy.
• APC possesses both anticoagulant and signaling properties, with the latter being crucial for anti-inflammatory effects.

Purpose of the Study:

• To review protein engineering strategies for improving recombinant APC therapeutics.
• To explore methods for separating APC's anticoagulant and signaling activities to mitigate bleeding risk.
• To discuss approaches for enhancing APC's cytoprotective signaling for improved therapeutic efficacy.

Main Methods:

• Review of existing literature on protein engineering of APC.
• Analysis of studies separating APC's distinct anticoagulant and signaling functions.
• Examination of current research enhancing APC's cytoprotective signaling pathways.

Main Results:

• Protein engineering can effectively separate APC's anticoagulant and signaling functions.
• Engineered APC variants demonstrate potential for reduced bleeding risk.
• Enhanced cytoprotective signaling in novel APC variants may increase therapeutic efficacy.

Conclusions:

• Protein engineering offers a viable strategy to overcome limitations of previous APC therapies.
• Novel engineered APC variants represent a promising next step for safer and more effective treatment.
• These advancements could benefit diseases where APC plays a protective role.